169 related articles for article (PubMed ID: 12558570)
1. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid.
Coupez R; Nicolas JM; Browne TR
Epilepsia; 2003 Feb; 44(2):171-8. PubMed ID: 12558570
[TBL] [Abstract][Full Text] [Related]
2. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy.
Otoul C; De Smedt H; Stockis A
Epilepsia; 2007 Nov; 48(11):2111-5. PubMed ID: 17651416
[TBL] [Abstract][Full Text] [Related]
3. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
4. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate.
Fountain NB; Conry JA; Rodríguez-Leyva I; Gutierrez-Moctezuma J; Salas E; Coupez R; Stockis A; Lu ZS
Epilepsy Res; 2007 Apr; 74(1):60-9. PubMed ID: 17270398
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic study of levetiracetam in children.
Pellock JM; Glauser TA; Bebin EM; Fountain NB; Ritter FJ; Coupez RM; Shields WD
Epilepsia; 2001 Dec; 42(12):1574-9. PubMed ID: 11879369
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of levetiracetam in Japanese and Western adults.
Pigeolet E; Jacqmin P; Sargentini-Maier ML; Stockis A
Clin Pharmacokinet; 2007; 46(6):503-12. PubMed ID: 17518509
[TBL] [Abstract][Full Text] [Related]
7. Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas.
Fay MA; Sheth RD; Gidal BE
Clin Ther; 2005 May; 27(5):594-8. PubMed ID: 15978308
[TBL] [Abstract][Full Text] [Related]
8. Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, Paeoniae Radix, in healthy volunteers.
Chen LC; Chou MH; Lin MF; Yang LL
J Clin Pharm Ther; 2000 Dec; 25(6):453-9. PubMed ID: 11123499
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
Chhun S; Jullien V; Rey E; Dulac O; Chiron C; Pons G
Epilepsia; 2009 May; 50(5):1150-7. PubMed ID: 19175400
[TBL] [Abstract][Full Text] [Related]
10. Comparison of reproductive effects of levetiracetam and valproate studied in prepubertal porcine ovarian follicular cells.
Taubøll E; Gregoraszczuk EL; Tworzydø A; Wójtowicz AK; Ropstad E
Epilepsia; 2006 Sep; 47(9):1580-3. PubMed ID: 16981877
[TBL] [Abstract][Full Text] [Related]
11. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin.
Ragueneau-Majlessi I; Levy RH; Meyerhoff C
Epilepsy Res; 2001 Nov; 47(1-2):55-63. PubMed ID: 11673021
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus.
Uges JW; van Huizen MD; Engelsman J; Wilms EB; Touw DJ; Peeters E; Vecht CJ
Epilepsia; 2009 Mar; 50(3):415-21. PubMed ID: 19054418
[TBL] [Abstract][Full Text] [Related]
13. Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication.
May TW; Rambeck B; Jürgens U
Ther Drug Monit; 2003 Dec; 25(6):690-9. PubMed ID: 14639055
[TBL] [Abstract][Full Text] [Related]
14. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Ramael S; Daoust A; Otoul C; Toublanc N; Troenaru M; Lu ZS; Stockis A
Epilepsia; 2006 Jul; 47(7):1128-35. PubMed ID: 16886975
[TBL] [Abstract][Full Text] [Related]
15. Development of tolerance during chronic treatment of kindled rats with the novel antiepileptic drug levetiracetam.
Löscher W; Hönack D
Epilepsia; 2000 Dec; 41(12):1499-506. PubMed ID: 11114206
[TBL] [Abstract][Full Text] [Related]
16. Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers.
Addison RS; Parker-Scott SL; Eadie MJ; Hooper WD; Dickinson RG
Eur J Clin Pharmacol; 2000 Dec; 56(9-10):715-21. PubMed ID: 11214782
[TBL] [Abstract][Full Text] [Related]
17. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials.
Perucca E; Gidal BE; Baltès E
Epilepsy Res; 2003 Feb; 53(1-2):47-56. PubMed ID: 12576167
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis.
Luszczki JJ; Andres MM; Czuczwar P; Cioczek-Czuczwar A; Ratnaraj N; Patsalos PN; Czuczwar SJ
Epilepsia; 2006 Jan; 47(1):10-20. PubMed ID: 16417526
[TBL] [Abstract][Full Text] [Related]
19. Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs.
Ji-qun C; Ishihara K; Nagayama T; Serikawa T; Sasa M
Epilepsia; 2005 Sep; 46(9):1362-70. PubMed ID: 16146430
[TBL] [Abstract][Full Text] [Related]
20. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers.
Levy RH; Ragueneau-Majlessi I; Baltes E
Epilepsy Res; 2001 Aug; 46(2):93-9. PubMed ID: 11463510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
